Allogene Therapeutics Inc (ALLO) saw an uptrend of 3.25% in the recent trading with $1.27 being its most recent. The current price level -66.40% lower than the highest price of $3.78 marked by the stock while trading over the past 52-weeks, whereas it is 47.31% higher than the lowest price of $0.86 the company dropped to over past 52-weeks. The latest news story on ALLO appeared in (Zacks) under the title “Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain” on.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 6 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.69 for the stock.
Allogene Therapeutics Inc Earnings – What Happened With ALLO
Coming around sales and income figures on ALLO Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Allogene Therapeutics Inc (ALLO) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 19.52% for net revenue.
ALLO – Allogene Therapeutics Inc Stock Earnings Estimates
The perspective of Allogene Therapeutics Inc (NASDAQ:ALLO)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.33 for stock’s EPS in the current quarter. Allogene Therapeutics Inc (ALLO) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 19.52% for net revenue. Company’s EPS for the last quarter was -0.27.
Allogene Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 220.13 million. ALLO does have institutional investors; and they hold 60.65% of the stock.
As on 2024-06-30, FMR LLC was the top most holder in Allogene Therapeutics Inc (NASDAQ:ALLO) with an ownership of 31.26 million shares of the company or 16.4491 of the stake worth $72.83 million. The filing also reveals TPG GP A, LLC as the second largest holder in the company with a control over 9.8493 of the outstanding shares. Its stake is worth $43.61 million for having 18.72 million shares in hand.
BLACKROCK INC. also came holding a key position in the company during the recent quarter and it now holds 8.6544 of the outstanding shares. With this there are now 211.0 institutions which have possession in ALLO’s shares.
Key Metrics for ALLO
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Allogene Therapeutics Inc has a debt to equity ratio of 0.25.
